Progyny, Inc. (NASDAQ:PGNY) Receives $24.82 Average Price Target from Analysts

Shares of Progyny, Inc. (NASDAQ:PGNY) have earned a consensus rating of “Hold” from the thirteen ratings firms that are presently covering the firm, MarketBeat reports. Nine research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $24.82.

Several equities research analysts recently commented on the company. Canaccord Genuity Group increased their price target on Progyny from $17.00 to $23.00 and gave the company a “hold” rating in a report on Friday, February 28th. JPMorgan Chase & Co. raised their target price on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Finally, Bank of America raised their target price on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, February 11th.

Insider Transactions at Progyny

In other news, Chairman David J. Schlanger purchased 150,000 shares of the stock in a transaction dated Thursday, December 26th. The stock was acquired at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the transaction, the chairman now directly owns 228,269 shares in the company, valued at approximately $3,350,988.92. This represents a 191.65 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Peter Anevski bought 209,500 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was bought at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the acquisition, the chief executive officer now owns 441,463 shares of the company’s stock, valued at $6,392,384.24. This trade represents a 90.32 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company’s stock.

Institutional Trading of Progyny

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Progyny by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 8,692,132 shares of the company’s stock worth $149,939,000 after acquiring an additional 48,271 shares during the last quarter. Pacer Advisors Inc. lifted its position in shares of Progyny by 47.5% during the 4th quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company’s stock worth $63,414,000 after purchasing an additional 1,183,558 shares during the last quarter. State Street Corp grew its stake in shares of Progyny by 4.5% during the third quarter. State Street Corp now owns 3,113,654 shares of the company’s stock worth $52,185,000 after purchasing an additional 134,861 shares in the last quarter. Invenomic Capital Management LP purchased a new position in Progyny in the third quarter valued at $29,509,000. Finally, River Road Asset Management LLC purchased a new position in Progyny in the fourth quarter valued at $25,529,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Stock Performance

NASDAQ:PGNY opened at $21.86 on Thursday. Progyny has a one year low of $13.39 and a one year high of $38.98. The stock has a market cap of $1.87 billion, a PE ratio of 37.69, a P/E/G ratio of 2.39 and a beta of 1.41. The stock has a 50 day moving average price of $21.93 and a 200 day moving average price of $18.59.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.